The NRFC commits $150 million to Brandon Capital to help create and scale the next generation of Australian medical breakthroughs.
The partnership supports the NRFC’s medical science priority area and will accelerate the creation and commercialisation of Australian-developed innovations including therapeutics, medical devices, and vaccines.
The funding will be allocated to Australian investments within the Brandon BioCatalyst 6 (BB6) fund and will help:
- Back early and late-stage Australian medical science companies
- Enable technical and clinical development
- Create high-value, skilled jobs in medical innovation
- Support business formation and spark commercial growth
- Position Australia as a global hub for advanced medical science and health technology
While the NRFC’s investment allocation will primarily help late-stage ventures to grow, complete clinical development and pursue regulatory approval, a third of the funding will also be dedicated to early-stage ventures to help support the next generation of medical breakthroughs.
The NRFC’s investment will bolster Australia’s sovereign medical manufacturing capability, building long-term resilience in the nation’s medical science ecosystem, while helping to crowd-in future private capital.
Australian medical manufacturing makes up only 0.3 per cent of the nation’s gross domestic product and this announcement marks a major step forward in translating world-class research into real-world health solutions.
About Brandon Capital
Brandon Capital is Australasia’s leading life sciences venture capital firm, with over $1 billion in funds under management it has offices in Australia, New Zealand, the United Kingdom, and the United States. The firm invests in early-stage and high-growth medical science companies providing them with the capital and expertise they need to transform their cutting-edge research into globally impactful medical products.
Brandon Capital has been transforming ANZ’s world-leading science into world-leading businesses for nearly two decades and through Brandon BioCatalyst, the medical research institute collaborative network they operate, Brandon Capital partners with entrepreneurs, researchers, and investors to build the next generation of healthcare solutions.